Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
humanized CD22 CAR-T
- Development stage
- Unknown
- Lead developer
- Shanghai YaKe Biotechnology
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Humanized CD22 CAR-T is an autologous chimeric antigen receptor (CAR) T-cell therapy developed by Shanghai YaKe Biotechnology. It is designed to target the CD22 antigen, a cell surface protein expressed on most B-cell malignancies. The CAR construct incorporates a humanized single-chain variable fragment (scFv) to minimize immunogenicity and potentially improve the persistence and efficacy of the T cells in the patient's body. This therapy is primarily being investigated for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL), particularly in patients who have experienced relapse following CD19-targeted CAR-T cell therapy.
- Other names
- humanized CD22-directed CAR-T cellsYaKe-CD22YaKe-CD-22YaKe-CD 22
02
Targets
CD22 (Cluster of Differentiation 22)
Beyond the preview
Go deeper on humanized CD22 CAR-T.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on humanized CD22 CAR-T.